Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2747)
All Articles published online
|
Aug 14, 2009 (publication date) through Nov 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Acosta MBD, Lorenzo A, Dominguez-Muñoz JE. Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009; 15(30): 3814-3816 [PMID: 19673025 DOI: 10.3748/wjg.15.3814] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i30/3814.htm |
| Number | Citing Articles |
| 1 |
Walter Reinisch. Crohn's Disease and Ulcerative Colitis. 2017; : 435 doi: 10.1007/978-3-319-33703-6_43
|
| 2 |
Z. Arora, B. Shen. Biological therapy for ulcerative colitis. Gastroenterology Report 2015; 3(2): 103 doi: 10.1093/gastro/gou070
|
| 3 |
Brijen Shah, Lloyd Mayer. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Review of Clinical Immunology 2010; 6(4): 607 doi: 10.1586/eci.10.45
|
| 4 |
Marisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás, Pilar Nos. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. Journal of Gastroenterology 2017; 52(7): 788 doi: 10.1007/s00535-016-1274-1
|
| 5 |
Gionata Fiorino, Laurent Peyrin-Biroulet, Alessandro Repici, Alberto Malesci, Silvio Danese. Adalimumab in ulcerative colitis: hypes and hopes. Expert Opinion on Biological Therapy 2011; 11(1): 109 doi: 10.1517/14712598.2011.541435
|
| 6 |
Bruno Rafael Ramos de Mattos, Maellin Pereira Gracindo Garcia, Julia Bier Nogueira, Lisiery Negrini Paiatto, Cassia Galdino Albuquerque, Caique Lopes Souza, Luís Gustavo Romani Fernandes, Wirla Maria da Silva Cunha Tamashiro, Patricia Ucelli Simioni, Even Fossum. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators of Inflammation 2015; 2015(1) doi: 10.1155/2015/493012
|
| 7 |
Yago González-Lama, María Isabel Vera, Marta Calvo, Lluís Abreu. Marcadores de evolución de la enfermedad inflamatoria intestinal tratada con inmunomoduladores o agentes biológicos. Gastroenterología y Hepatología 2010; 33(6): 449 doi: 10.1016/j.gastrohep.2009.11.005
|
| 8 |
Natalia López-Palacios, Juan L. Mendoza, Carlos Taxonera, Raquel Lana, José Miguel Esteban López-Jamar, Manuel Díaz-Rubio. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. European Journal of Internal Medicine 2011; 22(6): 621 doi: 10.1016/j.ejim.2011.06.017
|
| 9 |
William J. Sandborn, Gert van Assche, Walter Reinisch, Jean–Frederic Colombel, Geert D’Haens, Douglas C. Wolf, Martina Kron, Mary Beth Tighe, Andreas Lazar, Roopal B. Thakkar. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2012; 142(2): 257 doi: 10.1053/j.gastro.2011.10.032
|
| 10 |
Ming-Hsi Wang, Jean-Paul Achkar. Medical Therapy of Ulcerative Colitis. 2014; : 185 doi: 10.1007/978-1-4939-1677-1_16
|
| 11 |
Manuel Barreiro-de Acosta, Orlando García-Bosch, Jordi Gordillo, Miriam Mañosa, Luis Menchén, Raquel Souto, Ignacio Marin-Jimenez. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab. European Journal of Gastroenterology & Hepatology 2012; 24(7): 756 doi: 10.1097/MEG.0b013e3283525a7b
|
| 12 |
Stefano Nobile, Paolo Gionchetti, Fernando Rizzello, Carlo Calabrese, Massimo Campieri. Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy. European Journal of Gastroenterology & Hepatology 2014; 26(4): 458 doi: 10.1097/MEG.0000000000000045
|
| 13 |
Mark A. Samaan, Preet Bagi, Niels Vande Casteele, Geert R. D’Haens, Barrett G. Levesque. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014; 43(3): 479 doi: 10.1016/j.gtc.2014.05.006
|
| 14 |
Edmée C.M. Sikkens, Djuna L. Cahen, Casper van Eijck, Ernst J. Kuipers, Marco J. Bruno. The Daily Practice of Pancreatic Enzyme Replacement Therapy After Pancreatic Surgery: a Northern European Survey. Journal of Gastrointestinal Surgery 2012; 16(8): 1487 doi: 10.1007/s11605-012-1927-1
|
| 15 |
Walter Reinisch. Crohn's Disease and Ulcerative Colitis. 2012; : 495 doi: 10.1007/978-1-4614-0998-4_41
|
| 16 |
Silvio Danese. Adalimumab in ulcerative colitis: Ready for prime time. Digestive and Liver Disease 2013; 45(1): 8 doi: 10.1016/j.dld.2012.05.021
|
| 17 |
Ya-qian Jia, Zi-wen Yuan, Xiao-song Zhang, Jia-qi Dong, Xue-nan Liu, Xiao-ting Peng, Wan-ling Yao, Peng Ji, Yan-ming Wei, Yong-li Hua. Total alkaloids of Sophora alopecuroides L. ameliorated murine colitis by regulating bile acid metabolism and gut microbiota. Journal of Ethnopharmacology 2020; 255: 112775 doi: 10.1016/j.jep.2020.112775
|
| 18 |
Christopher Ma, Vivian Huang, Darryl K. Fedorak, Karen I. Kroeker, Levinus A. Dieleman, Brendan P. Halloran, Richard N. Fedorak. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. Journal of Clinical Gastroenterology 2015; 49(8): 675 doi: 10.1097/MCG.0000000000000265
|
| 19 |
Zong Mei Zhang, Wei Li, Xue Liang Jiang. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut and Liver 2016; 10(2): 262 doi: 10.5009/gnl15042
|
| 20 |
C. Taxonera, J. Estellés, I. Fernández-Blanco, O. Merino, I. Marín-Jiménez, M. Barreiro-de Acosta, C. Saro, V. García-Sánchez, E. Gento, G. Bastida, J. P. Gisbert, I. Vera, P. Martinez-Montiel, S. Garcia-Morán, M. C. Sánchez, J. L. Mendoza. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology & Therapeutics 2011; 33(3): 340 doi: 10.1111/j.1365-2036.2010.04531.x
|